Showing 2201-2210 of 9226 results for "".
- LEO Pharma Reports Positive Phase 2 Pediatric Data for Tralokinumab in Atopic Dermatitishttps://practicaldermatology.com/news/leo-pharma-reports-positive-phase-2-pediatric-data-for-tralokinumab-in-atopic-dermatitis/2487767/LEO Pharma has announced positive topline results from the Phase 2 TRAPEDS-1 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD).
- Consensus Panel Offers First Standardized Imaging Framework for High-Risk CSCChttps://practicaldermatology.com/news/consensus-panel-offers-first-standardized-imaging-framework-for-high-risk-cscc/2487708/A multidisciplinary panel of experts has developed consensus recommendations to help standardize staging and surveillance imaging for patients with localized cutaneous squamous cell carcinoma (cSCC), publishing the recommendations online in
- FDA Accepts sNDA for Roflumilast Cream 0.05% in Infants With ADhttps://practicaldermatology.com/news/fda-accepts-snda-for-zoryve-cream-005-in-infants-with-atopic-dermatitis/2487703/The US Food and Drug Administration (FDA) anounced that it has accepted Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) seeking to expand the indication for ZORYVE (roflumilast) cream 0.05% to include infants aged 3 to 24 months with mild to mode
- Teva Advances Anti-IL-15 Antibody Into Phase 2b for Vitiligohttps://practicaldermatology.com/news/teva-advances-anti-il-15-antibody-into-phase-2b-for-vitiligo/2487696/Teva Pharmaceutical Industries Ltd. has announced plans to advance its investigational anti-interleukin-15 (IL-15) monoclonal antibody (TEV-'408) into a Phase 2b clinical trial for non-segmental vitiligo (NSV) in the fourth quarter of 2026 following encouraging in
- Commentary Proposes Path to Cutting Plastic Waste in Dermatology Researchhttps://practicaldermatology.com/news/commentary-highlights-practical-route-to-cutting-plastic-waste-in-dermatology-research/2487685/The redesign of laboratory packaging to reduce plastic waste is a feasible near-term strategy for reducing plastic waste in skin-model research without disrupting validated experimental systems, according to a commentary in the Journal of Investigative Dermato
- Study: Dupilumab Shows Long-Term Disease Control in Pediatric Atopic Dermatitishttps://practicaldermatology.com/news/study-dupilumab-shows-long-term-disease-control-in-pediatric-atopic-dermatitis/2487681/Children and adolescents with moderate-to-severe atopic dermatitis (AD) maintained improvements in disease signs and symptoms during 1 year of dupilumab treatment, according to a post hoc analysis of the ongoing phase 3 LIBERTY AD PED-OLE open-label extension study
- FDA Grants SKYRIZI Approval to Children With Plaque Psoriasis and PsAhttps://practicaldermatology.com/news/fda-expands-skyrizi-approval-to-include-children-with-plaque-psoriasis-and-psoriatic-arthritis/2487657/The FDA has expanded the indication for SKYRIZI® (risankizumab-rzaa) to include children aged 6 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, according to an announcement from AbbVie.
- Study Shows Racial Differences in Pseudofolliculitis Barbae Complications, Treatment Timinghttps://practicaldermatology.com/news/racial-differences-in-pfb-complications-treatment-timing-highlight-care-gaps/2487632/A multicenter retrospective cohort study published as a Letter to the Editor in the Journal of Drugs in Dermatology found that Black patients with pseudofolliculitis barbae (PFB) experienced significantly higher rates of post-inflammatory hyperpigmentation (PIH) and hypertrophic scarring
- Study: Off-Label Dosing Shows Limited Benefit for Brodalumab, Bimekizumab in Psoriasishttps://practicaldermatology.com/news/study-off-label-dosing-shows-limited-benefit-for-brodalumab-bimekizumab-in-psoriasis/2487623/A systematic review published in Archives of Dermatological Research suggested deviations from approved dosing schedules offered limited clinical advantage in patients with plaque psoriasis, while maintaining similar safety. Investigators reviewed randomized controlled trials and
- Letter Questions Strength of Evidence Linking Hair Relaxers to Uterine Cancerhttps://practicaldermatology.com/news/letter-questions-strength-of-evidence-linking-hair-relaxers-to-uterine-cancer/2487618/A recently published Letter to the Editor in the Journal of Drugs in Dermatology urged clinicians to interpret the growing body of research examining chemical hair relaxers and uterine cancer with caution, arguing that important methodological limitations prevent current evidence from es